Selective serotonin reuptake inhibitors (SSRIs) are among the most effective treatments for the pharmacological treatment of clinical anxiety. However, meaningful clinical improvements do not occur for several weeks in most patients and not at all in others. Moreover, a great deal of uncertainty exists as to how these compounds actually work. A significant obstacle to understanding the mechanism of clinical action, and to developing more efficacious and rapid-acting treatments, has been the lack of validated animal models of SSRI-sensitive anxiety. Over the last several years, we have obtained evidence that sustained increases in the amplitude of the acoustic startle response in response to long-duration threat stimuli are mediated by brain areas different from those which mediate shorter-duration phasic increases. The former type of response seems more akin to anxiety than to fear, and may be more suitable for detecting SSRImediated anxiolysis. Findings during the last grant period indicate that sustained startle increases are especially sensitive to corticotropin releasing factor type 1 receptor (CRF-R1) antagonists. In this application we will 1) compare the anxiolytic activity of two CRF-R1 receptor antagonists (GSK008 and CRF-002) in the sustained fear test;determine if sensitivity to CRF-R1 receptor blockade depends on conditioned fear stimulus duration during training or, alternatively, response duration during testing;and determine with greater precision the time-course over which potentiated startle becomes CRF-dependent, 2) Compare the efficacy and time-course of a mixed 5HTiA/iB/iD receptor antagonist (GSK-1) with that of the selective serotonin reuptake inhibitor (SSRI) escitalopram in disrupting phasic versus sustained fear, after acute versus chronic administration, 3) Evaluate the effect of acute versus chronic administration of GSK-1 and escitalopram in blocking CRF-enhanced startle and the effect of the CRF! receptor antagonist, GSK008, on the acute anxiogenic effects of escitalopram, 4) Evaluate over-expression of CRF in the central nucleus of the amygdala (CeA), using a CRF-producing lentiviral vector, as a novel model of anxiety in rats, and evaluate the effect of GSK008, CRF-002 and chronic administration of GSK-1 and escitalopram on measures of anxiety in these animals

Public Health Relevance

Anxiety disorders affect 19 million people in the US alone yet often go untreated because of medication side effects or treatment failures. The primary goal of this Center is to accelerate the development of novel drugs for the treatment of depression and anxiety. The goals of Project 1 are to preclinically evaluate the anxiolytic potential of three novel compounds and to use these compounds as tools to further explore what appear to be dissociable neural substrates of fear- versus anxiety-like responses.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19MH069056-10
Application #
8522308
Study Section
Special Emphasis Panel (ZMH1-ERB-S)
Project Start
Project End
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
10
Fiscal Year
2013
Total Cost
$312,777
Indirect Cost
$100,693
Name
Emory University
Department
Type
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Pape, Julius C; Carrillo-Roa, Tania; Rothbaum, Barbara O et al. (2018) DNA methylation levels are associated with CRF1 receptor antagonist treatment outcome in women with post-traumatic stress disorder. Clin Epigenetics 10:136
Hodgins, Gabrielle E; Blommel, Jared G; Dunlop, Boadie W et al. (2018) Placebo Effects Across Self-Report, Clinician Rating, and Objective Performance Tasks Among Women With Post-Traumatic Stress Disorder: Investigation of Placebo Response in a Pharmacological Treatment Study of Post-Traumatic Stress Disorder. J Clin Psychopharmacol 38:200-206
Dunlop, Boadie W; Binder, Elisabeth B; Iosifescu, Dan et al. (2017) Corticotropin-Releasing Factor Receptor 1 Antagonism Is Ineffective for Women With Posttraumatic Stress Disorder. Biol Psychiatry 82:866-874
Maples-Keller, Jessica L; Price, Matthew; Rauch, Sheila et al. (2017) Investigating Relationships Between PTSD Symptom Clusters Within Virtual Reality Exposure Therapy for OEF/OIF Veterans. Behav Ther 48:147-155
Guo, Ji-Dong; O'Flaherty, Brendan M; Rainnie, Donald G (2017) Serotonin gating of cortical and thalamic glutamate inputs onto principal neurons of the basolateral amygdala. Neuropharmacology 126:224-232
Norrholm, Seth Davin; Jovanovic, Tanja; Gerardi, Maryrose et al. (2016) Baseline psychophysiological and cortisol reactivity as a predictor of PTSD treatment outcome in virtual reality exposure therapy. Behav Res Ther 82:28-37
Price, Matthew; Maples, Jessica L; Jovanovic, Tanja et al. (2015) An investigation of outcome expectancies as a predictor of treatment response for combat veterans with PTSD: comparison of clinician, self-report, and biological measures. Depress Anxiety 32:392-9
Grillon, Christian; Hale, Elizabeth; Lieberman, Lynne et al. (2015) The CRH1 antagonist GSK561679 increases human fear but not anxiety as assessed by startle. Neuropsychopharmacology 40:1064-71
Ridgewell, Caitlin; Bray, Allison; Curtis, Kaylah et al. (2015) Enhanced Olfactory Cortex Connectivity in a Patient With PTSD With Olfactory Hallucinations. J Neuropsychiatry Clin Neurosci 27:e170-1
Stehouwer, Jeffrey S; Bourke, Chase H; Owens, Michael J et al. (2015) Synthesis, binding affinity, radiolabeling, and microPET evaluation of 4-(2-substituted-4-substituted)-8-(dialkylamino)-6-methyl-1-substituted-3,4-dihydropyrido[2,3-b]pyrazin-2(1H)-ones as ligands for brain corticotropin-releasing factor type-1 (CRF1) rec Bioorg Med Chem Lett 25:5111-4

Showing the most recent 10 out of 57 publications